Pentadeca Arginate (PDA) vs PT-141 (Bremelanotide)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Pentadeca Arginate (PDA)PT-141 (Bremelanotide)
CategoryPeptidesPeptides
Standard DoseResearch indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
TimingAdminister on an empty stomach. Inject near site of injury for localized effect.45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
Cycle Duration4-12 weeks depending on therapeutic target.As-needed basis. Not intended for daily use.
Evidence Levelanimal_plus_anecdotalstrong_human

Mechanism

Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.

Timing

Administer on an empty stomach. Inject near site of injury for localized effect.

Cycle Duration

4-12 weeks depending on therapeutic target.

Side Effects

  • Mild nausea (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuCJC-1295/Ipamorelin

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Standard Dosing

Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Timing

45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Cycle Duration

As-needed basis. Not intended for daily use.

Side Effects

  • Nausea (most common, dose-dependent)
  • Flushing
  • Headache
  • Nasal congestion (intranasal route)
  • Transient blood pressure increase
  • Skin darkening with repeated use

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Use of other melanocortin agonists concurrently

Best Stacking Partners

Kisspeptin-10Melanotan II

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →